Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Nov 10 - Nov 15
MOTS-c is a mitochondrial-derived peptide with AMPK-linked signaling, and AOD-9604 is a GH-fragment-derived lipolysis compound
You can find a complete list of necessary gear in our guide on essential-lab-equipment
The complete side effect frequency breakdown from Phase 2 trials: Very Common (20%+ of patients at 12mg dose) Nausea: 28% Typically mild to moderate, peaks weeks 4-8, usually resolves by week 12 Diarrhea: 24% Usually transient (1-3 weeks), rarely severe Constipation: 21% Paradoxically coexists with diarrhea in different patients Common (10-20% of patients) Vomiting: 17% Decreased appetite: 16% (beyond therapeutic effect) Injection site reactions: 14% Fatigue: 13% Dyspepsia (indigestion): 12% Headache: 11% Uncommon (2-10% of patients) Abdominal pain: 8% Dizziness: 7% Gastroesophageal reflux: 6% Hypoglycemia in diabetics on other medications: 5% Increased heart rate (average 2-4 bpm): 4% Hair thinning/loss: 3% (typically temporary) Rare but Serious (Under 2%) Pancreatitis: 0.3% (3 cases out of 1,032 patients, all resolved with discontinuation) Gallbladder events: 1.4% (expected with rapid weight loss regardless of method) Acute kidney injury: 0.7% (all cases associated with severe dehydration) KEY TAKEAWAY: About 30% experience meaningful nausea in the first 4-8 weeks
Understanding Patient Needs for Frequency The most persistent complaint from PA patients is the lack of clinical support to receive more frequent injections when their symptoms demand it
US$ 21.33
US$ 29.47
US$ 25.77
US$ 27.72
US$ 29.38
US$ 23.97
